【摘要】：目的:比較瑞格列奈分別聯(lián)合氨氯地平、氯沙坦鉀治療2型糖尿病(T2DM)合并原發(fā)性高血壓的療效和安全性。方法:306例T2DM合并原發(fā)性高血壓患者隨機(jī)分為A組(153例)和B組(153例)。兩組患者均采用常規(guī)飲食運(yùn)動(dòng)療法及胰島素治療,入院后給予瑞格列奈片1 mg,口服,每日1次;在此基礎(chǔ)上,A組患者給予苯磺酸左旋氨氯地平片2.5 mg,口服,每日1次;B組患者給予氯沙坦鉀片50 mg,口服,每日1次。兩組療程均為8周。觀察兩組患者的臨床療效,治療前后血壓水平、血糖水平、腎功能指標(biāo)(血肌酐、血尿酸、血尿素氮、尿微量蛋白)、舒張期左心室厚度及不良反應(yīng)發(fā)生情況。結(jié)果:兩組患者總有效率比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。治療前,兩組患者血壓水平、血糖水平、腎功能指標(biāo)、舒張期左心室厚度比較,差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,兩組患者血壓水平、血糖水平、腎功能指標(biāo)、舒張期左心室厚度均顯著低于同組治療前,且A組血肌酐、尿微量蛋白顯著低于B組,B組舒張期左心室厚度顯著低于A組,差異均有統(tǒng)計(jì)學(xué)意義(P0.05),但兩組間血壓水平、血糖水平、血尿酸、血尿素氮比較差異均無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者不良反應(yīng)發(fā)生率比較,差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論:瑞格列奈聯(lián)合氨氯地平與瑞格列奈聯(lián)合氯沙坦鉀治療T2DM合并原發(fā)性高血壓的療效和安全性均相當(dāng),但瑞格列奈聯(lián)合氨氯地平在降低尿微量蛋白水平、改善腎功能方面優(yōu)于瑞格列奈聯(lián)合氯沙坦鉀,瑞格列奈聯(lián)合氯沙坦鉀在延緩左心室重構(gòu)、保護(hù)心臟功能方面優(yōu)于瑞格列奈聯(lián)合氨氯地平。
[Abstract]:Aim: to compare the efficacy and safety of repaglinide combined with amlodipine and losartan potassium in the treatment of type 2 diabetes mellitus (T2DM) with essential hypertension. Methods 306 T2DM patients with essential hypertension were randomly divided into group A (153 cases) and group B (153 cases). The patients in both groups were treated with routine diet exercise therapy and insulin therapy. After admission, patients in group A were given levamlodipine benzenesulfonic acid for 2. 5 mg, and repaglinide was given orally for 1 mg, once a day, on the basis of which patients in group A were given levamlodipine benzenesulfonate for 2. 5 mg,. Patients in group B were given losartan potassium tablets once a day for 50 mg,. The course of treatment was 8 weeks in both groups. The clinical efficacy, blood pressure level, blood glucose level, renal function index (serum creatinine, serum uric acid, blood urea nitrogen, urine trace protein), diastolic left ventricular thickness and adverse reaction were observed. Results: there was no significant difference in the total effective rate between the two groups (P0.05). Before treatment, there was no significant difference in blood pressure, blood glucose, renal function and diastolic left ventricular thickness between the two groups (P0.05). After treatment, the blood pressure level, blood glucose level, renal function index, diastolic left ventricular thickness in both groups were significantly lower than those before treatment in the same group, and the serum creatinine in group A was significantly lower than that in the same group. The left ventricular thickness in group B was significantly lower than that in group B (P0.05), but there was no significant difference in blood pressure level, blood glucose level, uric acid and blood urea nitrogen between the two groups (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion: the efficacy and safety of repaglinide combined with amlodipine and repaglinide combined with losartan potassium in the treatment of T2DM with essential hypertension are equal, but repaglinide combined with amlodipine can reduce the level of urinary trace protein. The improvement of renal function was superior to that of repaglinide combined with losartan potassium, repaglinide combined with losartan potassium in delaying left ventricular remodeling and protecting heart function than repaglinide combined with amlodipine.
【作者單位】： 重慶醫(yī)科大學(xué)附屬第一醫(yī)院第一分院;重慶市第五人民醫(yī)院心內(nèi)科;
【分類(lèi)號(hào)】：R587.1;R544.11

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 王淑芳,王少蓮;瑞格列奈治療初發(fā)老年2型糖尿病臨床研究[J];中國(guó)老年學(xué)雜志;2004年06期

2 馬秀萍,張友遜,李程乾;瑞格列奈治療2型糖尿病患者的療效觀察[J];疑難病雜志;2004年06期

3 龔旭紅;瑞格列奈治療2型糖尿病療效觀察[J];安徽醫(yī)學(xué);2005年02期

4 包曉燕;;瑞格列奈治療2型糖尿病臨床效果觀察[J];中國(guó)民族民間醫(yī)藥;2009年22期

5 ;非磺脲類(lèi)胰島素促泌劑瑞格列奈臨床應(yīng)用共識(shí)[J];中國(guó)全科醫(yī)學(xué);2010年16期

6 符文燕;賈冬;;瑞格列奈治療2型糖尿病68例療效觀察[J];中國(guó)臨床研究;2010年10期

7 周?chē)?guó)灶;;瑞格列奈治療2型糖尿病患者55例臨床分析[J];中國(guó)實(shí)用醫(yī)藥;2011年26期

8 浙江省瑞格列奈臨床觀察協(xié)作組;;國(guó)產(chǎn)瑞格列奈治療老年2型糖尿病的有效性和安全性研究[J];中國(guó)糖尿病雜志;2012年04期

9 王春波;;瑞格列奈治療46例2型糖尿病的療效觀察[J];中國(guó)醫(yī)藥指南;2012年10期

10 劉河;董永勝;劉田雨;;瑞格列奈治療2型糖尿病的臨床證據(jù)評(píng)價(jià)[J];中國(guó)醫(yī)藥指南;2013年10期

相關(guān)會(huì)議論文 前10條

1 李仁祥;張貴根;楊士聰;張燕;官建雄;唐冠德;;瑞格列奈及制劑研究概述[A];海南省藥學(xué)會(huì)2011年學(xué)術(shù)年會(huì)論文集[C];2011年

2 王先令;陸菊明;竇京濤;母義明;巴建明;潘長(zhǎng)玉;;應(yīng)用動(dòng)態(tài)血糖監(jiān)測(cè)系統(tǒng)評(píng)價(jià)瑞格列奈治療新診斷2型糖尿病的療效[A];2006年中華醫(yī)學(xué)會(huì)糖尿病分會(huì)第十次全國(guó)糖尿病學(xué)術(shù)會(huì)議論文集[C];2006年

3 張和義;;瑞格列奈聯(lián)合二甲雙胍治療2型糖尿病66例體會(huì)[A];浙江省第十九屆農(nóng)村衛(wèi)生改革與發(fā)展學(xué)術(shù)會(huì)議大會(huì)論文集[C];2011年

4 梁慧;張萍;藍(lán)海云;陳奇盛;;瑞格列奈治療2型糖尿病的臨床療效觀察[A];中華醫(yī)學(xué)會(huì)第六次全國(guó)內(nèi)分泌學(xué)術(shù)會(huì)議論文匯編[C];2001年

5 王凌;;瑞格列奈治療老年2型糖尿病臨床療效觀察[A];第七屆全國(guó)老年醫(yī)學(xué)進(jìn)展學(xué)術(shù)會(huì)議論文集[C];2007年

6 婁志宏;;瑞格列奈在糖尿病治療中的應(yīng)用進(jìn)展[A];2012年中國(guó)藥學(xué)大會(huì)暨第十二屆中國(guó)藥師周論文集[C];2012年

7 宋欽華;宋安華;王轉(zhuǎn)鎖;陳z，

本文編號(hào)：2224551